Karyopharm to Report Data From Phase 3 Trial of Selinexor Plus Ruxolitinib in Myelofibrosis
MT Newswires Live
Jun 02
Karyopharm Therapeutics (KPTI) said Tuesday that a late-breaking abstract from its phase 3 trial of selinexor combined with ruxolitinib in myelofibrosis was accepted for an oral presentation at the 2026 European Hematology Association Congress in mid-June.
The company said new data will highlight a post-hoc analysis of 24 patients from phase 1 of the trial, which indicates that achieving a spleen volume reduction of 35% or more may predict overall survival, consistent with a similar analysis from the phase 3 trial.
Shares of Karyopharm Therapeutics were down more than 8% in Tuesday trading.
Price: 8.99, Change: -0.84, Percent Change: -8.50
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.